Brinzolamide Added to C2 PHARMA Ophthalmic Portfolio
The carbonic anhydrase inhibitor has been finalized for production to treat high intraocular pressure.
Updated on Oct. 1, 2026 in Asthma
C2 PHARMA has officially added the carbonic anhydrase inhibitor Brinzolamide to its portfolio of ophthalmic active pharmaceutical ingredients. This expansion aims to provide cost-competitive treatment options for individuals managing elevated eye pressure.
Why it matters
By filing a U.S. Drug Master File and finalizing production protocols, the company is positioning this medication for future availability in the global market. This development supports ongoing efforts to expand access to standard care for glaucoma and ocular hypertension.
C2 PHARMA successfully completed a process validation campaign in September 2026 for Brinzolamide. The filing of a U.S. Drug Master File serves as the regulatory basis for the company to supply the ingredient.
The players
C2 PHARMA
An Ireland-based pharmaceutical company that manufactures and supplies active pharmaceutical ingredients for various therapeutic areas.
Haleos Labs Limited
A pharmaceutical manufacturing partner specializing in the production and supply of medical ingredients.
The details
Brinzolamide functions as a carbonic anhydrase inhibitor, which helps lower elevated intraocular pressure by reducing the production of aqueous humor in the eye. The manufacturing process for this ingredient is being carried out through a partnership with Haleos Labs Limited to ensure standardized production quality. This collaborative approach marks a final step in the company's internal validation phase before the ingredient enters broader supply chains.
Timeline
September 2026: The process validation campaign for Brinzolamide was finalized.
October 1, 2026: C2 PHARMA formally announced the addition of Brinzolamide to its portfolio.
October 6, 2026 - October 8, 2026: C2 PHARMA team members scheduled to attend CPHI Milan.
Health Landscape
The introduction of this carbonic anhydrase inhibitor follows a broader trend of companies seeking to bolster the supply of critical ingredients for chronic eye conditions. This move reflects the ongoing evolution of global manufacturing partnerships within the specialized ophthalmic medicine market.
Brinzolamide is used to treat ocular conditions like glaucoma by reducing fluid pressure within the eye. If you currently use medications to manage your intraocular pressure, any changes in your treatment plan or medication brand should be discussed directly with your ophthalmologist.
The takeaway
Maintaining target intraocular pressure is essential for preventing the progression of vision-related damage in glaucoma. Keep a record of your current eye drop prescriptions and schedule regular pressure checks with your eye care specialist to monitor your long-term eye health.
Further reading
For more information on managing chronic conditions affecting the eyes and airways, visit our Asthma section.
